

# Eosinophilia-Myalgia Syndrome

[View the current Eosinophilia-Myalgia Syndrome InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Eosinophilia-Myalgia_Syndrome.html) (PDF)  
([http://www.bioportfolio.com/indepth/Eosinophilia-Myalgia\\_Syndrome.html](http://www.bioportfolio.com/indepth/Eosinophilia-Myalgia_Syndrome.html)) - Regularly Updated.

## Recent Publications on Eosinophilia-Myalgia Syndrome:



- [Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms.](#)  
*OBJECTIVE: To assess L-tryptophan (LT) dose, age, sex, and immunogenetic...*18th November, 2009  
Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Japan.- *Arthritis Rheum.* 2009 Oct 15;61(10):1305-11. ([DOI Direct Link](#))
- [Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease?](#)  
*An 11-year-old girl with a calpain-3 gene (CAPN-3) mutation and...*29th July, 2009  
Department of Neurology, Neuromuscular Unit, Istanbul University, Istanbul- *Neuromuscul Disord.* 2009 Apr;19(4):261-3. Epub 2009 Mar 13. ([DOI Direct Link](#))
- [\[Shulman's syndrome \(eosinophilic fasciitis\)\]](#)  
*Eosinophilic fasciitis is a rare disease characterized by edema, painful...*7th July, 2009  
Hautklinik, Universitatsklinikum Dusseldorf, Moorenstr. 5, 40225- *Hautarzt.* 2009 Apr;60(4):278-81. ([DOI Direct Link](#))
- [Neuromuscular disorders associated with apical hypertrophic cardiomyopathy.](#)  
*BACKGROUND: Cardiomyopathy is a frequent manifestation of neuromuscular...*6th June, 2009  
Krankenanstalt- *Acta Cardiol.* 2009 Feb;64(1):85-9.
- [Food contamination.](#)  
*OBJECTIVE: To assess L-tryptophan (LT) dose, age, sex, and immunogenetic...*7th May, 2009  
Department of Adolescent Medicine, Childrens Hospital Los Angeles, Los- *Dis Mon.* 2009 May;55(5):263-91. ([DOI Direct Link](#))
- [Review article toxic oil syndrome: review of immune aspects of the disease.](#)  
*In 1981-1982, individuals in fourteen central and northwest provinces in...*30th October, 2008  
Laboratory of Molecular Toxicology, Environmental Toxicology Program,- *J Immunotoxicol.* 2005 Jan 1;2(1):51-8. ([DOI Direct Link](#))
- [\[Current differential diagnosis of hypereosinophilic syndrome\]](#)  
*INTRODUCTION: Hypereosinophilic syndrome (HES) is a group of idiopathic...*10th September, 2008  
Klinika za hematologiju, Klinicki centar Vojvodine, Novi Sad.- *Med Pregl.* 2007 Nov-Dec;60(11-12):581-6.
- [Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations.](#)  
*BACKGROUND: At present, the pharmacological activity of drugs in inducing...*3rd September, 2008  
University of Medicine, Department of Dermatology and Venereology, 1 St- *Expert Opin Drug Saf.* 2008

- Jul;7(4):421-33. ([DOI Direct Link](#))
- [\[Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake\]](#)  
*Eosinophilia-myalgia syndrome was described in 1989 in patients who...*19th July, 2008  
Departamento de Clinica Medica, Faculdade de Ciencias Medicas,- J Bras Pneumol. 2007  
Dec;33(6):747-51.
  - [\[Scleroderma-like disorders.\]](#)  
*Fibrosing disorders comprise a wide spectrum of heterogeneous diseases...*17th July, 2008  
Rheumatology Unit, Azienda Ospedaliera Universitaria V. Emanuele,- Autoimmun Rev. 2008  
Feb;7(4):331-9. Epub 2008 Jan 11. ([DOI Direct Link](#))
  - [\[Generation of quinoneimine intermediates in the bioactivation of 3-\(N-phenylamino\)alanine \(PAA\) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.\]](#)  
*Eosinophilia-myalgia syndrome (EMS) was an intoxication episode that...*21st December, 2007  
Department of Biological Organic Chemistry, Institut d'Investigacions- Chem Res Toxicol. 2007  
Oct;20(10):1556-62. Epub 2007 Sep 25. ([DOI Direct Link](#))
  - [\[Strain-dependent acute lung injury after intra-tracheal administration of a 'refined' aniline-denatured rapeseed oil: a murine model of the toxic oil syndrome?\]](#)  
*Most attempts to reproduce the toxic oil syndrome in animals, either with...*14th December, 2007  
Laboratory of Lung Toxicology, K.U. Leuven, Leuven, Belgium.- Food Chem Toxicol. 2007  
Dec;45(12):2563-73. Epub 2007 Jul 4. ([DOI Direct Link](#))
  - [\[Part II. Eosinophilia-Myalgia Syndrome: further correlations between compromised histamine degradation, eosinophilias and myopathies.\]](#)  
*Eosinophilia-myalgia syndrome (EMS) was an intoxication episode that...*31st October, 2007  
Division of Natural Products, Center for Food Safety and Applied- Inflamm Res. 2007 Apr;56 Suppl  
1:S7-8.
  - [\[Diagnostic problems in eosinophilic fasciitis\]](#)  
*We presented two cases with symptoms of diffuse swelling of subcutaneous...*27th July, 2007  
Katedra i Klinika Reumatologiczno-Rehabilitacyjna i Chorob Wewnetrznych- Pol Arch Med Wewn. 2006  
Aug;116(2):777-80.
  - [\[Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report.\]](#)  
*Eosinophilia-myalgia syndrome (EMS) often is a disabling disorder caused...*11th November, 2006  
Department of Dermatology, Mount Sinai Medical Center, One Gustave L. Levy- Cutis. 2006  
Jun;77(6):361-4.

## Eosinophilia-Myalgia Syndrome Patents:



- 7230133- [Malonamides and malonamide derivatives as modulators of chemokine receptor activity](#)
- 7338975- [Lactams as modulators of chemokine receptor activity](#)
- 7351720- [N-ureidoalkyl-piperidines as modulators of chemokine receptor activity](#)
- 7368527- [HADDE71 polypeptides](#)
- 7368531- [Human secreted proteins](#)
- 7378409- [Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity](#)
- 7381738- [Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity](#)

- 7381800- [Antibodies to HBIMF63 polypeptide](#)
- 7393934- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7449184- [Fixed dosing of HER antibodies](#)
- 7338947- [Cyclic derivatives as modulators of chemokine receptor activity](#)
- 7323311- [Methods of obtaining a specific binding member that binds eotaxin](#)
- 7317019- [N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7238660- [Albumin fusion proteins](#)
- 7238666- [Method of inhibiting fibrosis with a somatostatin agonist](#)
- 7238667- [Albumin fusion proteins](#)
- 7285526- [Interferon antagonists useful for the treatment of interferon related diseases](#)
- 7288563- [Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity](#)
- 7291615- [Cyclic derivatives as modulators of chemokine receptor activity](#)
- 7291744- [N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity](#)
- 7297099- [Use of osteopontin for the treatment and/or prevention of neurologic diseases](#)
- 7312222- [Heterocyclic piperidines as modulators of chemokine receptor activity](#)
- 7449493- [Diamines as modulators of chemokine receptor activity](#)
- 7459531- [50 Human secreted proteins](#)
- 7550500- [Bicyclic and tricyclic amines as modulators of chemokine receptor activity](#)
- 7560532- [Smad6 and uses thereof](#)
- 7569384- [Albumin fusion proteins](#)
- 7572813- [Cyclic derivatives as modulators of chemokine receptor activity](#)
- 7576089- [3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors](#)
- 7589066- [Potent and specific immunoproteasome inhibitors](#)
- 7592010- [Albumin fusion proteins](#)
- 7598287- [Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7601844- [Piperidinyl derivatives as modulators of chemokine receptor activity](#)
- 7550486- [N-ureidoalkyl-piperidines as modulators of chemokine receptor activity](#)
- 7544806- [Piperidine-substituted indoles-or heteroderivatives thereof](#)
- 7521424- [Albumin fusion proteins](#)
- 7468440- [Malonamides and malonamide derivatives as modulators of chemokine receptor activity](#)
- 7479496- [Substituted spiro azabicyclics as modulators of chemokine receptor activity](#)
- 7482013- [Albumin fusion proteins](#)
- 7482335- [Cyclic derivatives as modulators of chemokine receptor activity](#)
- 7491724- [Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases](#)
- 7501123- [Human G-protein chemokine receptor \(CCR5\) HDGNR10](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7511121- [Polymeric immunoglobulin fusion proteins that target low-affinity Fc.gamma.receptors](#)
- 7514430- [Piperizinones as modulators of chemokine receptor activity](#)
- 7615556- [Piperazinyl derivatives as modulators of chemokine receptor activity](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

